Worldwide Healthcare Trust PLC - Unaudited Results for the Six Months ended 30 September 2026
PR Newswire
LONDON, United Kingdom, November 18
LONDON STOCK EXCHANGE ANNOUNCEMENT
Worldwide Healthcare Trust PLC
(the "Company")
Unaudited Results for the Six Months ended
30 September 2026
The statements below are extracted from the Company's half-year report for the six months ended 30 September 2026 (the "Half Year Report"). This announcement contains references to graphs and charts which appear in the full Half Year Report, which will shortly be available on the Company's website: www.worldwidewh.com where up to date information on the Company, including daily NAV, share prices and fact sheets, can also be found.
The Half Year Report has been submitted to the Financial Conduct Authority, and will shortly be available for inspection on the National Storage Mechanism (NSM) at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information please contact: Mark Pope, Frostrow Capital LLP 0203 008 4913.
Performance
|
| SIX MONTHS TO | ONE YEAR TO |
|
| 30 SEPTEMBER | 31 MARCH |
|
| 2026 | 2026 |
Net asset value per share (total return)* # |
| +9.3% | +10.0% |
Share price (total return)* # |
| +14.8% | +13.1% |
Benchmark (total return)^ # |
| +9.9% | +1.8% |
| 30 SEPTEMBER | 31 MARCH | SIX MONTHS |
| 2026 | 2026 | CHANGE |
Net asset value per share | 403.6p | 371.0p | +8.8% |
Share price | 381.5p | 334.0p | +14.2% |
Discount of share price to the net asset value per share | (5.5)% | (10.0)% |
|
Leverage1 | 14.9% | 12.5% |
|
Ongoing charges* | 0.9% | 0.9% |
|
Ongoing charges (including performance fees crystallised during the period)* | 0.9% | 0.9% |
|
# Source - Morningstar.
^ Benchmark - MSCI World Health Care Index on a net total return, sterling adjusted basis (see Glossary).
* Alternative Performance Measure (See Glossary).
1 Leverage calculated under the Commitment Method (see Glossary).
Statement from the Chair
"During the first half of the financial year, the Company's net asset value per share total return was +9.3% and the share price total return was +14.8%, these compared to a return of +9.9% from the Company's Benchmark."
This is my first statement to shareholders of Worldwide Healthcare Trust PLC following my appointment as Chair at the conclusion of the Company's Annual General Meeting ("AGM") in July 2026. I am pleased to report that, against a backdrop of ongoing economic and geopolitical uncertainty, the Healthcare sector's long-term fundamentals remain compelling. Innovation across Pharmaceuticals, Biotechnology and Healthcare Services continues to create attractive opportunities for active investors. While market sentiment towards Healthcare stocks remained variable during the period, the Board remains confident in the Company's investment approach and long-term prospects.
PERFORMANCE
During the six-month period, global markets continued to be influenced by the evolving macroeconomic environment, the trajectory of interest rates, geopolitical developments and the ongoing impact of artificial intelligence-related investment. Whilst broader equity markets remained supported by resilient economic activity and generally healthy corporate earnings, investor sentiment continued to fluctuate in response to policy developments and concerns regarding economic growth in several major regions.
Against this backdrop, the performance of the Healthcare sector, which underperformed the broader market in the period, reflected a combination of policy, regulatory and company-specific factors. While the sector continued to benefit from strong levels of innovation, particularly in Biotechnology and precision medicine, investor attention (particularly in the first few months of the financial year) remained focused on issues such as drug pricing and the pace of regulatory approvals. Merger and acquisition activity remained an important feature of the Healthcare landscape, providing support for valuations across selected areas of the market.
In this environment, I am pleased to report that the Company's net asset value ("NAV") per share total return during the six months to 30 September 2026 was +9.3%, and the share price total return was 14.8%, these compared to a net total return of +9.9% from the Company's Benchmark, the MSCI World Health Care Index (sterling-adjusted), during the same period. The discount of the Company's share price to the NAV per share discount moved from 10.0% to 5.5% during the half year.
The Portfolio Manager continued to identify attractive opportunities across Healthcare subsectors and geographies while also maintaining the Company's long-standing emphasis on innovation, scientific advancement and long-term growth potential.
Looking at specific names in the portfolio, the top two contributions came from U.S. Pharmaceutical major Eli Lilly and U.S. Biotechnology company Natera. Theportfolio's proprietary swap basket of Biotechnology companies with the potential to be acquired also made a positive contribution to performance during the period. Meanwhile, the two principal detractors from performance were U.S. Medical Technology company Boston Scientific and Swedish-British multinational Pharmaceutical and Biotechnology company AstraZeneca. Further information on the Company's investments and performance can be found in the Portfolio Manager's Review.
As shareholders will be aware, leverage remains an important component of the Company's investment approach. Average leverage during the period was 14.9%, contributing 1.1% to overall performance. At the half-year end, leverage stood at 14.9%, compared with 12.5% at the start of the period.
PERFORMANCE FEE
No performance fee was accrued as at 30 September 2026 and no performance fee can become payable within the next year. The performance fee arrangements are described in detail in the Company's Annual Report.
CAPITAL
Share price discounts continued to be a prominent feature of the investment company sector during the period. As noted above, the Company's discount to NAV stood at 5.5% on 30 September 2026, this compares to an average share price discount in the sector of 11.8%. (source: Winterflood Investment Trusts).
The Board's policy remains to repurchase shares when the Company's discount to NAV exceeds 6% on an ongoing basis. Despite the Company's share buybacks, the discount can remain greater than 6% for extended periods of time, depending on overall sentiment towards the Company, the sector and investment companies generally. Whilst share buybacks cannot entirely offset wider market sentiment towards investment companies, they enhance NAV per share for continuing shareholders and remain an important mechanism in the management of the discount.
During the period, the Company repurchased a total of 31,330,075 shares for treasury at a cost of £115.9m and at an average discount of 7.2%. At the period end, there were 342,082,342 shares in issue (excluding the 259,582,858 shares held in treasury). From the period end to 16 November 2026, a further 7,776,867 shares have been bought back for treasury, at a cost of £30.0m and at an average discount of 7.5%.
The Board remains committed to its discount control policy and will continue to monitor market conditions closely while balancing the interests of both existing and prospective shareholders.
The Company's share buyback authority will, as usual, be proposed for renewal at the Company's AGM to be held on Tuesday,13 July 2027.
DIVIDENDS
The Board has declared an unchanged interim dividend of 0.7p per share, for the year to 31 March 2027. It will be payable on 8 January 2027 to shareholders on the register of members on 27 November 2026, with an ex-dividend date of 26 November 2026.
The Board continues to believe that shareholders' long-term interests are best served by maximising opportunities for capital growth through investment in the portfolio rather than targeting a particular dividend yield. Accordingly, the Company's dividend policy remains focused on maintaining investment trust status and distributing income in accordance with applicable requirements.
COMPOSITION OF THE BOARD AND PORTFOLIO MANAGEMENT RESPONSIBILITIES
As I have mentioned, I succeeded Doug McCutcheon as Chair of the Board when he retired from the Board at the conclusion of the AGM in July. On behalf of the Board and Shareholders, I would like to thank Doug for his leadership, commitment and the hugely valuable contribution he made to the Company throughout his tenure.
We also announced, in August, that Sven Borho was stepping down as the Company's lead portfolio manager, and he retired from the Board on 30 October 2026. Sven was involved in the growth and strategy of the Company since its inception in 1995 and served as a Director for the last eight years. On behalf of the Board, I would like to express gratitude to Sven for his significant efforts on behalf of the Company throughout that time.
We shall miss the contributions of Doug and Sven, both in Board meetings, and outside.
We were, however, delighted that Trevor Polischuk, who was previously co-portfolio manager with Sven, agreed to take on the role of lead portfolio manager in August and we announced the appointment of Geoff Hsu as his co-portfolio manager at the same time. Trevor and Geoff both know the Company's portfolio well and the Company's investment approach has not changed as a result of Sven's retirement.
OUTLOOK
The Board remains confident in the long-term investment case for the global Healthcare sector.
Healthcare continues to benefit from powerful structural growth drivers, including ageing populations, rising Healthcare expenditure, increasing demand for innovative therapies and rapid advances in medical science and technology. In addition, the pace of innovation across areas such as oncology, obesity treatments, precision medicine and artificial intelligence-enabled Healthcare remains compelling.
Whilst periods of market volatility are likely to persist, the Board believes that current valuations across parts of the Healthcare sector continue to present attractive opportunities for active investors. We therefore remain confident in the Portfolio Manager's ability to generate attractive long-term returns through disciplined stock selection and effective capital allocation.
As I begin my tenure as Chair, I do so with confidence in the Company's strategy, the strength and depth of its portfolio, and the expertise of the Portfolio Manager, all set against this positive backdrop for the Healthcare sector.
I look forward to engaging with shareholders in the years ahead and thank you for your continued support of the Company.
William Hemmings
Chair
17 November 2026
Portfolio
AS AT 30 SEPTEMBER 2026
|
|
| Market value | % of |
Investments | Sector | Country/region | £'000 | investments |
Eli Lilly | Pharmaceuticals | United States | 199,195 | 14.1 |
Merck | Pharmaceuticals | United States | 97,328 | 6.9 |
Novartis | Pharmaceuticals | Switzerland | 76,268 | 5.4 |
UnitedHealth | Health Care Providers & Services | United States | 59,027 | 4.2 |
Thermo Fisher Scientific | Life Sciences Tools & Services | United States | 55,013 | 4.0 |
AbbVie | Pharmaceuticals | United States | 46,079 | 3.3 |
Natera | Life Sciences Tools & Services | United States | 44,831 | 3.2 |
Edwards Lifesciences | Health Care Equipment & Supplies | United States | 44,247 | 3.1 |
Galderma | Pharmaceuticals | Switzerland | 42,781 | 3.0 |
AstraZeneca | Pharmaceuticals | Britain | 41,212 | 2.9 |
Top 10 investments |
|
| 705,981 | 50.1 |
Guardant Health | Life Sciences Tools & Services | United States | 40,963 | 2.9 |
Argenx | Biotechnology | Belgium | 40,627 | 2.9 |
Abbott Laboratories | Health Care Equipment & Supplies | United States | 40,165 | 2.8 |
Humana | Health Care Providers & Services | United States | 36,739 | 2.6 |
Caris Life Sciences | Life Sciences Tools & Services | United States | 34,448 | 2.4 |
Daiichi Sankyo | Pharmaceuticals | Japan | 30,361 | 2.3 |
Sanofi | Pharmaceuticals | France | 29,255 | 2.1 |
Bayer | Pharmaceuticals | Germany | 29,101 | 2.1 |
Chugai Pharmaceutical | Pharmaceuticals | Japan | 28,048 | 2.1 |
Ascendis Pharma | Biotechnology | Denmark | 27,988 | 2.1 |
Top 20 investments |
|
| 1,043,674 | 74.4 |
Travere Therapeutics | Biotechnology | United States | 27,649 | 2.0 |
Cogent Biosciences | Biotechnology | United States | 25,277 | 1.8 |
Intuitive Surgical | Health Care Equipment & Supplies | United States | 24,178 | 1.7 |
Jazz Pharmaceuticals | Pharmaceuticals | Ireland | 23,800 | 1.7 |
Arcutis Biotherapeutics | Biotechnology | United States | 23,060 | 1.6 |
Tango Therapeutics | Biotechnology | United States | 21,753 | 1.5 |
Praxis Precision Medicines | Biotechnology | United States | 20,410 | 1.4 |
West Pharmaceutical Services | Life Sciences Tools & Services | United States | 18,733 | 1.3 |
Structure Therapeutics | Biotechnology | United States | 18,313 | 1.3 |
Shanghai INT Medical Instruments | Health Care Equipment & Supplies | China | 18,257 | 1.3 |
Top 30 investments |
|
| 1,265,104 | 90.0 |
CareDx | Life Sciences Tools & Services | United States | 17,457 | 1.2 |
Mineralys Therapeutics | Biotechnology | United States | 14,876 | 1.1 |
Dexcom | Health Care Equipment & Supplies | United States | 14,810 | 1.1 |
Hangzhou Tigermed Consulting | Life Sciences Tools & Services | China | 14,521 | 1.0 |
Waters | Life Sciences Tools & Services | United States | 13,323 | 0.9 |
Beijing Yuanxin Technology* | Health Care Providers & Services | China | 12,854 | 0.9 |
EDDA Healthcare & Technology* | Health Care Equipment & Supplies | China | 11,804 | 0.8 |
CVS Health | Health Care Providers & Services | United States | 11,780 | 0.8 |
Rhythm Pharmaceuticals | Biotechnology | United States | 7,490 | 0.5 |
Abivax SA | Biotechnology | France | 7,453 | 0.5 |
Top 40 investments |
|
| 1,391,472 | 98.8 |
Axsome Therapeutics | Biotechnology | United States | 7,438 | 0.5 |
uniQure NV | Biotechnology | Netherlands | 7,181 | 0.5 |
Ruipeng Pet* | Health Care Providers & Services | China | 6,874 | 0.5 |
API Holdings* | Health Care Providers & Services | India | 4,576 | 0.3 |
Visen Pharmaceuticals | Biotechnology | China | 1,905 | 0.1 |
Peloton Therapeutics - Milestone* | Biotechnology | United States | 1,524 | 0.1 |
ImageneBio | Biotechnology | United States | 467 | 0.0 |
Total investments |
|
| 1,421,436 | 100.8 |
Biotech M&A Target Swap | Swap Baskets | United States | 146,746 | 10.4 |
Wuxi Apptec | Health Care Providers & Services | China | 14,828 | 1.1 |
Asymchem Laboratories | Pharmaceuticals | China | 3,776 | 0.3 |
Less: Gross exposure on financed swaps |
|
| (176,736) | (12.6) |
Total OTC Swaps |
|
| (11,386) | (0.8) |
Total investments including OTC Swaps |
|
| 1,410,050 | 100.0 |
* Unquoted holding
SUMMARY
| Market value | % of |
Investments | £'000 | investments |
Quoted Equities | 1,383,804 | 98.2 |
Unquoted Equities | 37,632 | 2.6 |
Equity Swaps | (11,386) | (0.8) |
Total of all investments | 1,410,050 | 100.0 |
Portfolio Manager's Review
MARKETS
Global equity markets started the reported period in a depressed state with the commencement of the U.S. conflict with Iran in late February 2026. "Operation Epic Fury" triggered a significant sell-off in March and the MSCI World Index fell as much as 7% (sterling) as investors de-risked fearing the worst. Nevertheless, markets quickly rebounded with the start of the financial year as concerns surrounding the conflict moderated, oil prices retreated from their initial spike, corporate earnings remained resilient, and investors resumed the pursuit of returns in artificial intelligence ("AI").
Overall, equity markets delivered strong positive returns during the six-month period, recovering sharply from the sell-off associated with the outbreak of the Iran conflict. The MSCI World Index advanced approximately 15.7% (sterling) in the period ended 30 September 2026, reaching multiple all-time highs, including on 13 August 2026.
Healthcare equities also delivered strong positive returns during the six-month period, with the MSCI World Health Care Index advancing 9.9% in sterling terms and on a net total return basis. Whilst Healthcare participated in the global equity market recovery, the sector materially underperformed the broader market, particularly during the first two months of the period.
This relative weakness largely represented a reversal of the preceding six months, when healthcare equities significantly outperformed the broader market. This period of outperformance followed the first of 17 pharmaceutical pricing and tariff agreements with the Trump administration, announced on 30 September 2025. Additionally, even as the broader market collapsed in March 2026 due to the Iran conflict, specific subsectors within Healthcare - most notably Biotechnology - demonstrated remarkable resilience, insulated by a historic wave of merger and acquisition ("M&A") activity that highlighted the high demand for therapeutic innovation.
ALLOCATION
We utilise a two-pronged approach to allocation in the portfolio. First, we have a long-standing, strategic "recipe for success" in which we overweight Biotechnology exposure and underweight Pharmaceutical exposure, both a nod to relative Benchmark weights but also to how we view the respective fundamentals of the companies populating these sectors. Second, we maintain the tactical ability to alter weightings in response to shifting fundamentals and macro-factors that can inform our views across the Healthcare investment landscape.
The most critical element of the portfolio's allocation was the maintenance of a structural overweight position in Biotechnology, specifically targeting Emerging Biotechnology companies, reflecting our bullishness around the enormous therapeutic innovation and new drug opportunities emanating from the sector and the relatively small weight that is represented in the Benchmark. However, we did tactically lower our exposure here through the half year. First, in July after Biotechnology stocks reached a 52-week high in (as per the XBI*) and particularly in September, after a confirmed U.S. interest rate increase negatively impacted Biotechnology sentiment. At the end of the half year, the portfolio held a 27.8% absolute weight in Biotechnology (compared to the Benchmark weight of 11.0%), down almost 3% from the start of the financial year and down approximately 7.5% from the intra-period high.
Within the broader Pharmaceuticals sub-sector, the portfolio maintained a selective posture and remained structurally underweight during the half year. The portfolio's strategy avoids passive exposure to Pharmaceuticals, instead concentrating capital exclusively in the industry's "Haves": companies possessing industry leading drug discovery, pipelines, development, pricing, new product flow, and dominant positions in growth categories such as oncology, rare diseases, immunology, and cardiometabolic disorders. This selective approach allowed the portfolio to maximise exposure to superior commercial execution while minimising the drag of sector-wide patent expirations.
However, given the positive resolutions for both federal drug pricing and the stay on Pharmaceutical tariffs, and accelerating innovation in Pharma-pipelines, we materially increased our weighting here. Overall, we closed the half-year period with a weighting of 42.3% in Pharmaceuticals, representing an approximately 8.5% increase from the start of year positioning but still notably below the Benchmark weight of 50.5%.
Positioning in the Life Science Tools & Diagnostics sector increased materially in the period due to our enthusiasm for the accelerating awareness of liquid biopsy and its utilisation in the Healthcare ecosystem. Both tactical buys and share price appreciation across four key companies (GuardantHealth, Natera, Caris Life Sciences, and CareDx) contributedto an increased overweight position of 16.2% versus a Benchmark weight of 10.3% as of the end of September. This contrasts to an equal weight positioning at the start of the financial year.
* An exchange-traded fund designed to track the performance of the Biotechnology Industry.
The allocation to Medical Technology required the most tactical manoeuvring during the financial year. The portfolio entered the period with an overweight position, anticipating a potential improvement, if not an outright recovery, in global surgical procedure volumes and the acceleration of specific new product super-cycles in cardiovascular and robotic surgery. However, this did not materialise and thus we systematically reduced our exposure throughout the six-month period, moving to an underweight position in May. By the end of September 2026, the portfolio's weighting had been reduced to 8.9% from almost 18.8% at the beginning of the year, partially mitigating the portfolio from additional drawdowns in the sector. The Benchmark weighting at the period end was 12.7%.
Allocation Summary - WWH vs MSCI World HC Index
(as of 30 September 2026)
Subsector | Change vs 31 Mar 2026 | WWH | MSCI World HC | Delta |
Pharmaceuticals | +910 bps | 43.2 | 50.6 | (7.4) |
Large Pharma |
| 37.4 | 46.4 | (9.0) |
Spec Pharma/Generics |
| 5.8 | 4.1 | 1.7 |
Biotechnology | -390 bps | 27.9 | 11.0 | 16.9 |
Large Biotech |
| 0.0 | 7.9 | (7.9) |
Emerging Biotech |
| 27.9 | 3.1 | 24.8 |
Life Science Tools & Diagnostics | +730 bps | 16.2 | 10.3 | 5.9 |
Medical Technology* | -990 bps | 8.9 | 12.7 | (3.8) |
Healthcare Services | +420 bps | 7.8 | 12.1 | (4.3) |
Japan | +190 bps | 4.2 | 3.3 | 0.9 |
Emerging Markets | -640 bps | 3.9 | 0.0 | 3.9 |
Privates | NM | 2.7 | 0.0 | 2.7 |
Total |
| 114.9 | 100.0 | 14.9 |
*Medical Technology also known as Healthcare Equipment & Supplies
Exposure to Healthcare Services remained structurally underweight throughout the period although we did increase exposure by over 4% in the period. This was principally due to a constructive view on the Medicare pricing environment in the U.S. and building overweight positions in UnitedHealth and Humana (who both possess significant exposure to Medicare Advantage). Meanwhile we remained cautious on hospitals, distributors, and other Healthcare insurers, and thus remained net underweight the broader Healthcare Services sector.
In Japan, our exposure effectively doubled during the period to 4.2% following the addition of Chugai Pharmaceutical, bringing the number of Japanese holdings to two. This selective approach reflects the Trust's longstanding investment philosophy of concentrating capital in our highest-conviction ideas, rather than seeking broad geographic diversification.
Finally, we reduced exposure in Emerging Markets. Whilst we remain convinced regarding the quality and speed of clinical innovation coming from China Biotechnology companies, the overhang of geopolitical tensions between east and west inflected in 2026, with threats of political interference that may impede or outright negate business and licensing deals going forward.
Otherwise, our geographic split between U.S. and Europe/U.K. domiciled companies did not materially change. U.S. exposure edged higher reflecting our rotation out of China and an increase in leverage from the start of the financial year, whilst the mix between U.S./Europe remained roughly constant.
PERFORMANCE
The six-month period ended 30 September 2026 was characterised by strong absolute returns for global Healthcare equities, although significant market volatility and pronounced shifts in investor sentiment created a challenging backdrop for active portfolio management. During the period, the Company's net asset value (NAV) per share delivered a total return of +9.3%, compared with a return of +9.9% for the MSCI World Health Care Index (the "Benchmark"), representing relative underperformance of 0.6%. All performance figures are expressed in sterling, on a total return basis.
Importantly, the period comprised two distinct phases, with very different market conditions and investment outcomes. Following the outbreak of the conflict in Iran in March 2026, global equity markets initially experienced considerable volatility before staging a broad-based recovery. During April and May, however, Healthcare equities generally lagged the wider market as investors favoured technology and other growth-oriented sectors. This relative weakness was particularly notable given Healthcare's traditional reputation as a defensive investment during periods of geopolitical uncertainty.
The turning point came in late May when investor sentiment towards healthcare began to improve materially. A combination of renewed enthusiasm for Biotechnology, increasing M&A activity, and a rotation away from technology stocks sparked a powerful rally across several Healthcare sub-sectors.
The Trust was particularly well-positioned to benefit from this change in sentiment. Between 31 March and 7 July 2026, the Trust delivered a NAV total return of +15.4%, substantially outperforming the Benchmark's return of +9.0%, representing an excess return of 6.4%. This period demonstrated the significant upside potential of the Trust's active investment approach, particularly its exposure to innovative Biotechnology companies and its differentiated positioning in Life Science Tools and Diagnostics.
The second phase of the period, from early July through the end of September, proved considerably more challenging. Following a powerful rally that had taken Biotechnology shares to 52-week highs, investors increasingly sought to crystallise profits, resulting in a meaningful correction across parts of the sector. This was accompanied by continued market volatility and periodic rotations between Healthcare sub-sectors.
During this latter period, the Trust's NAV per share total return was -5.4%, compared with a modest gain of 0.9% for the Benchmark, resulting in relative underperformance of approximately 6.2%. Consequently, the substantial relative outperformance generated during the first three months of the period was surrendered.
Nevertheless, the Trust maintained a strong positive absolute return for the half year. We view this performance as encouraging given the considerable volatility experienced across global healthcare markets, while recognising that the reversal in relative performance during the second half of the period was disappointing.
Taking a broader perspective, performance over the past 18 months better illustrates the growing momentum in Healthcare equities, particularly since the sector's inflection point in September 2025, notwithstanding periods of geopolitically driven market volatility. Since 1 April 2025, the Trust has delivered a NAV total return exceeding 20% (sterling), outperforming the Benchmark by more than 8%.
Several powerful catalysts have underpinned this performance, including robust M&A activity, accelerating innovation across Biopharmaceutical pipelines, greater regulatory clarity and stability surrounding U.S. prescription drug pricing, and a sustained pace of new medicine approvals by the U.S. Food and Drug Administration ("FDA") at historically elevated levels. Collectively, these developments have helped restore investor confidence in the sector's long-term growth prospects and reinforce our conviction that healthcare remains one of the most compelling investment opportunities in global equities.
Taking an even longer-term perspective, we are pleased to report another milestone in the Trust's strong performance since inception. Over the past 30.5 years, the Trust has delivered a cumulative NAV total return of +5,229%, equivalent to a compound annual growth rate ("CAGR") of 13.4%, compared with a Benchmark return of +2,746%, or 11.1% annualised (all figures in sterling). The most recent period included reaching a record high closing NAV per share, achieved 19 August 2026. This sustained outperformance underscores the enduring value of our disciplined, bottom-up investment approach and our focus on identifying transformative Healthcare innovation.
A notable inflection point in both absolute and relative performance emerged towards the end of the 2000s, coinciding with the maturation of the genomic revolution and profound advances in our understanding of human biology. These scientific breakthroughs ushered in a new era of biopharmaceutical innovation, characterised by increasingly sophisticated drug development pipelines, novel therapeutic modalities and more precisely targeted medicines. The benefits of this transformation continue to resonate today and are now being further amplified by the rapid adoption of AI across Healthcare, creating exciting new opportunities to accelerate drug discovery, enhance clinical development and ultimately improve patient outcomes. We believe these powerful forces will continue to underpin attractive long-term investment opportunities for the Trust.
SUB-SECTOR CONTRIBUTION/ATTRIBUTION
Performance across the Trust's Healthcare sub-sectors was notably divergent, reflecting the importance of stock selection, portfolio positioning and the timing of shifts in investor sentiment.
Life Science Tools and Diagnostics wasthe standout contributor, generating approximately 6.3% of absolute return and 3.6% of excess return relative to the Benchmark. This strong performance was driven by the Trust's exposure to innovative diagnostic technologies, particularly companies pioneering liquid biopsy, molecular diagnostics and precision medicine.
We have maintained a strong conviction that advances in molecular diagnostics represent one of the most attractive secular growth opportunities in Healthcare. The increasing use of blood-based testing to detect, monitor and manage disease has the potential to transform patient outcomes while creating substantial new commercial markets.
Importantly, the portfolio's exposure to this theme proved particularly rewarding during the period, with Natera, Guardant Health and Caris Life Sciences ranking among theportfolio's largest individual contributors.
Pharmaceuticals contributed approximately3.7% to absolute returns, although the sector detracted approximately 1.1% from relative performance. While several of our pharmaceutical investments performed strongly, most notably Eli Lilly, Merck and Novo Nordisk, the Trust's continued underweight exposure to large-cap Pharmaceuticals was a headwind as the sector delivered positive returns.
We continue to favour Pharmaceutical companies with differentiated pipelines, accelerating new product launches and attractive long-term earnings growth prospects. Nevertheless, we remain selective, recognising that the significant valuation differences across the industry present both opportunities and risks.
Healthcare Services contributedapproximately 2.0% to the Trust's absolute return, but detracted 0.3% on a relative basis. Humana was a particularly notable contributor, benefiting from improving investor sentiment towards the managed care industry. The sector nevertheless remained sensitive to changes in medical utilisation trends, reimbursement expectations and government healthcare policy.
Biotechnology made a positive contributionof approximately 1.2%, with broadly neutral relative performance over the six-month period. The first half of the period was characterised by strong gains across innovative Biotechnology companies, supported by positive clinical developments, improving sentiment and an acceleration in merger and acquisition activity. However, much of this strength was subsequently reversed as investors took profits following the sector's powerful rally and the interest rate increase by the U.S. Federal Reserve.
Our proprietary Biotechnology M&A strategy, implemented through the "MANA" swap basket, generated 1.0% (of the 1.2%) absolute contribution. This strategy reflects our view that innovative small- and mid-cap Biotechnology companies represent an attractive source of external innovation for larger pharmaceutical companies. We continue to believe that industry consolidation will remain an important driver of shareholder value, particularly given the need for large Pharmaceutical companies to replenish their pipelines and offset future patent expirations.
Medical Technology was the principal areaof weakness, detracting approximately 2.7% from absolute performance and 1.7% from relative returns. The sector continued to face challenges as investors questioned the sustainability of growth expectations, hospital capital spending and the valuations of several leading medical technology companies. Boston Scientific was the portfolio's largest individual detractor, while Intuitive Surgical and Stryker also negatively affected performance.
Despite these setbacks, we remain constructive on the longer-term prospects for medical technology, where advances in minimally invasive procedures, robotics and other innovative treatment modalities continue to offer meaningful growth opportunities. However, the investment environment has become increasingly discriminating, placing greater importance on earnings delivery, valuation discipline, and the durability of competitive advantages, much of which was lacking so far in 2026.
Outside the major developed markets, Emerging Markets detracted approximately 0.5% from both absolute and relative performance. Our exposure to Japan also modestly detracted from absolute returns, by approximately 0.2%, while having a broadly neutral impact on relative performance.
Collectively, these results illustrate both the benefits and challenges of the Trust's differentiated portfolio construction. Our strongest areas of stock selection, particularly within Life Science Tools and Diagnostics,
generated substantial outperformance, but this was offset by weakness in Medical Technology and the effects of our portfolio positioning in other sub-sectors.
PRIVATE HOLDINGS
For the six months ended 30 September 2026, the Company strategically refrained from making new investments in unquoted companies. Whilst we continue to see significant improvement in the capital markets for small and mid-cap healthcare companies, we have remained on the sidelines with respect to new unquoted investments. For the period, the unquoted portfolio did not have any exits. We are confident that more of the Company's unquoted investments will achieve listings within the next year as the capital market funding environment further improves.
At the end of the half-year period ended 30 September 2026, unquoted investments made up 2.6% of the portfolio, similar to the exposure at the end of the previous financial year end. For the six months ended 30 September 2026, the market value of the Company's unquoted investments increased by £1.1 million, from an opening value of £36.5 million across five companies.
The remaining unquoted portfolio is concentrated in Healthcare Services and Medical Technology, with a smaller exposure to Biotechnology. Geographically, exposure is predominantly in Emerging Markets, with a minor allocation to a North American company.
MAJOR CONTRIBUTORS TO PERFORMANCE
Concerns that the obesity treatment revolution might prove short-lived have increasingly been dispelled by sustained global demand and a growing body of clinical evidence demonstrating health benefits beyond weight loss, including in cardiovascular and sleep-related conditions. Eli Lilly remains a global leader in this rapidly expanding market, with a commanding position in injectable treatments through Mounjaro and Zepbound, the successful introduction of its oral GLP-1 medicine, Foundayo (orforglipron), and a promising next-generation pipeline, including retatrutide, a novel triple-hormone receptor agonist, and eloralintide, a novel selective, long-acting amylin receptor agonist.
This momentum has translated into exceptional financial performance. Revenue increased 45% in 2025 to U.S.$65.2 billion, while operating income more than doubled. Growth continued into the first half of 2026, with revenue increasing 51% to U.S.$42.8 billion, driven primarily by strong global demand for Mounjaro and Zepbound. Importantly, robust volume growth has more than offset lower realised prices, demonstrating the underlying strength of the market. Following successive quarterly results, management raised full-year 2026 revenue guidance by a cumulative U.S.$4.5 billion to U.S.$85-87 billion, representing approximately 30-33% growth over 2025, alongside continued operating margin expansion.
The shares underwent a significant re-rating during the period, supported by exceptional first-quarter results, including revenue growth of 56% and a U.S.$2 billion increase in full-year sales guidance. This was followed by another strong second quarter, with revenue growth of 48% and a further increase in guidance. The U.S. approval and launch of Foundayo in April 2026 provided an additional growth opportunity beyond injectable therapies, while positive Phase 3 results for retatrutide reinforced confidence in the depth of Lilly's obesity pipeline and its ability to sustain innovation over the longer term.
Overall, shares in Eli Lilly advanced 26.2% during the period (total return, local currency) and were the largest contributor to the Company's performance. We remain bullish on Lilly's long-term prospects, supported by expanding globaldemand for obesity medicines, an increasing range of therapeutic applications, strong commercial execution and a differentiated pipeline. While pricing pressure and competition remain considerations, we believe Lilly's scale, manufacturing investments and continued innovation position the company to maintain a leading role in this rapidly growing market.
Minimal residual disease (MRD) testing remains one of the most promising areas of innovation within specialty diagnostics, with adoption still at an early stage. Natera was a leading contributor to portfolio performance, reflecting its position in this emerging market. Its Signatera blood test detects trace amounts of cancer-associated DNA after treatment that may be undetectable by conventional imaging, providing information about the risk of recurrence. A growing body of clinical evidence supports Signatera's use at multiple points along the cancer-care continuum.
Natera's commercial execution remained strong in theperiod as Signatera volumes accelerated quarter-over-quarter to 34,000 tests, exceeding market expectations. In May, Signatera became the first FDA-approved blood-based MRD companion diagnostic for identifying certain patients eligible for immuno-therapy (Tecentriq) following bladder removal. In June, independent cancer guidelines recommended Signatera-directed adjuvant Tecentriq treatment which further reinforced its clinical relevance. These milestones supported the share price over the past six months and could support broader physician adoption of MRD-guided treatment decisions over time.
Natera continues to expand its reimbursement opportunitiesbeyond established indications such as colorectal cancer, while advancing an early cancer-detection screening programme with data expected in 2027. The company has also expanded internationally, including a Signatera launch in Japan. We modestly reduced the position following second-quarter results and strength across liquid biopsy stocks, but Natera remains a core Tools and Diagnostics holding. We continue to view MRD as an underpenetrated market in which Natera is well positioned.
Guardant Health was another top contributor, underscoringthe portfolio's exposure to liquid biopsy innovation. The company has built a broad oncology testing portfolio spanning Guardant360 Liquid CDx for therapy selection, Shield for colorectal cancer screening, and Guardant Reveal for MRD detection and recurrence monitoring. Increasing utilisation across these products has supported strong revenue growth and share-price performance.
In the second quarter of 2026, oncology testing volumes rose 63% year over year, supported by continued Guardant360 adoption and more than a doubling of Reveal volumes. Shield screening volumes increased more than fourfold to 66,000 tests. These trends contributed to 44% revenue growth and an increase in full-year guidance. Future opportunities include the planned second-half 2026 launch of Reveal Ultra, a next-generation tumour-informed MRD assay, and progress toward an FDA submission for ShieldMulti-Cancer Detection.
Guardant is also investing in its AI-enabledSmart Platform,which draws on a multimodal dataset comprising more than one million longitudinal patient samples. We believe this resource could improve existing assays and create opportunities for pharmaceutical data partnerships, potentially creating a new revenue arm. We trimmed the position modestly after its strong performance but remain meaningfully overweight. Our conviction reflects the breadth of Guardant's portfolio, its potential path toward profitability, and anticipated Guardant360 pricing benefits in 2027.
Caris Life Sciences is a leader in tissue-based comprehensivemolecular profiling through its MI Profile offering, with emerging initiatives in multi-cancer early detection (MCED) and MRD. Its whole-exome and whole-transcriptome sequencing approach differentiates its molecular profiling offering. Following its July 2025 public listing, clinical volume growth finally began accelerating in the second quarter of 2026 after weather-related disruption in the first quarter. Caris reported approximately 59,200 clinical cases in the second quarter, an increase of roughly 18% year-over-year.
This year, the company expanded its sales and marketing efforts considerably across the U.S. and we expect the expanded commercial footprint to support volume growth in the second half of the financial year. The company also launched CarisDetect, a cash-pay MCED test priced at approximately U.S.$3,500,and expects to introduce a highly sensitive, tumour-informed pan-cancer MRD assay later in 2026.
To note, Caris Life Sciences positions itself as an AI-enabled technology and biology platform, integrating molecular profiling with computational analysis. Its Caris Max platform combines deep sequencing and AI-based interpretation to help identify potential tumour targets. Its large multimodal dataset could also support higher-margin data-licensing partnerships. We have opportunistically trimmed the holding amid sector strength but remain constructive on the relative valuation and upcoming product catalysts, as well as the potential benefit of the sales force expansion into 2027.
Humana is one of the largest providers of MedicareAdvantage health insurance in the United States, with an expanding presence in primary care and healthcare services through its CenterWell platform. Following a challenging period characterised by elevated medical costs, declining profitability and disappointing Medicare Star Ratings, investor sentiment began to recover during the reporting period as confidence improved in the company's ability to restore margins and earnings growth. A key catalyst came in April 2026, when the Centres for Medicare & Medicaid Services finalised a 2.5% increase in Medicare Advantage payment rates for 2027, significantly above the initially proposed increase of just 0.09%. This provided meaningful relief to an industry facing sustained medical cost inflation and reinforced confidence in the longer-term earnings recovery. Humana also demonstrated encouraging operational progress, with individual Medicare Advantage membership expected to grow approximately 25% in 2026, supported by improved customer retention and new enrolment. The company continued to expand its CenterWell primary care platform, with patient growth of 27% during the first half of 2026.
Financial performance also provided reassurance that the company's turnaround remained on track. Second-quarter adjusted earnings per share reached U.S.$7.61, while the Insurance segment benefit ratio of 91.2% was consistent with management expectations. Despite ongoing pressure from reduced Medicare quality bonus payments, Humana reaffirmed its full-year 2026 adjusted earnings guidance of at least U.S.$9.00 per share. Importantly, management continued to target a return to sustainable pre-tax margins of at least 3% by 2028, supported by more disciplined pricing, benefit redesign, improved clinical outcomes and operating efficiencies.
Overall, Humana shares recovered substantially during the period, with the company contributing over 1.0% to the Company's NAV performance, making it the fifth-largest contributor. Whilst we remain constructive on Humana's longer-term recovery prospects, we did exit the position following the reported period, booking profits in October after the stock inflected another +15% after Humana scored above expectations in the Centres for Medicare & Medicaid Services rating programme.
MAJOR DETRACTORS TO PERFORMANCE
Boston Scientific is one of, if not, the pre-eminentcardiovascular medical device companies in the world. In 2026, however, the company faced repeated challenges that created a dramatic shift in the company's growth profile, eroding investor confidence, compressing the multiple, and a share price that has corrected >50% (local currency).
An unexpected deceleration of the company's Watchman franchise, a permanent, minimally invasive heart implant designed to reduce stroke risk in patients with non-valvular atrial fibrillation (AFib) dramatically impacted the growth profile of the company after a decade of accelerating growth. Volume growth for Watchman disappointed in 2026 amid lower utilisation, mixed clinical evidence, and increased competition. Revenues for another key franchise, Farapulse, a non-thermal cardiac ablation device to directly treat atrial fibrillation, also disappointed primarily due to market share losses to rival Abbott. In late August, a cyberattack of Boston Scientific's IT infrastructure disrupted manufacturing order processing and shipping for a critical period. Management subsequently indicated that third-quarter guidance was at risk.
While we continue to recognise Boston Scientific's leadership in their respective franchises, we exited the position given the combination of Watchman uncertainty, rising competition, and operational disruption. We will continue to monitor the Company as visibility improves.
AstraZeneca is a leading global Biopharmaceutical companywith a diversified portfolio spanning oncology, respiratory disease, cardiovascular/metabolic conditions, and rare diseases. Despite continued commercial execution and a broad pipeline of innovative medicines, the company's shares came under pressure during the reporting period following disappointing results from important late-stage clinical trials and speculation surrounding a potential transformational acquisition, which weighed on investor confidence in its future growth trajectory.
Whilst underlying financial performance remained resilient during the first half of 2026, clinical disappointments and merger speculation overshadowed this underlying progress. In July, the Phase 3 CARDIO-TTRansform trial evaluating Wainua (eplontersen) in transthyretin amyloid cardiomyopathy failed to meet its primary endpoint, limiting expectations for expansion into a significant cardiovascular market.
In August, reports came out that AstraZeneca had held discussions regarding a potential U.S.$400 billion combination with Bristol Myers Squibb, prompting a sharp sell-off in AstraZeneca shares of approximately 9% in a single trading session. Investors questioned the strategic rationale for such a large transaction, particularly given Bristol Myers Squibb's significant upcoming patent expirations and the potential financial and operational complexities of integrating the two companies. Although subsequent reports indicated that discussions were no longer ongoing, the episode weighed on investor sentiment.
In September, further disappointment followed when the Phase 3 SERENA-4 trial evaluating camizestrant in first-line advanced breast cancer failed to demonstrate a statistically significant improvement in progression-free survival. These setbacks were partially offset by positive Phase 3 results for tozorakimab in chronic obstructive pulmonary disease, reinforcing the breadth of AstraZeneca's respiratory pipeline.
Overall, AstraZeneca was the portfolio's second-largest detractor during the period, reducing Net Asset Value performance by 1.1%. While the clinical setbacks and acquisition speculation were disappointing, we continue to recognise the strength of AstraZeneca's diversified commercial portfolio, established oncology leadership and extensive late-stage pipeline. We remain constructive on the company's longer-term prospects, supported by continued commercial execution and opportunities for further pipeline innovation, while closely monitoring clinical development risks and capital allocation discipline.
Product innovation remains a critical driver of performance in Medical Technology, and Intuitive Surgical is a leading example. The company has a dominant position in soft-tissue robotic surgery, supported by a substantial installed base, clinician familiarity, and a recurring instruments-and-accessories business. Adoption of the da Vinci 5 platform has been particularly strong in the United States, with international expansion providing an additional long-term opportunity. In the first quarter of 2026, U.S. procedure growth of approximately 15% exceeded expectations, while instruments-and-accessories revenue rose 23% year over year, ahead of consensus.
The share price subsequently underperformed around its second-quarter results, which were softer than we had anticipated. U.S. procedure growth decelerated to approximately 11%, below market expectations in the mid-teens, against a backdrop of more cautious patient spending and macroeconomic uncertainty. China also remained challenging amid stronger local competition. We reduced our position following the quarter. Subsequently, we added back to the position on weakness, as multiple indicators suggested improving U.S. procedure trends and da Vinci system placements, against expectations that had reset lower following second-quarter results. We remain constructive on Intuitive's long-term opportunity, including new force-feedbackinstruments that could support pricing and help offset pressure from extended-use instrument programmes.
Whilst global demand for GLP-1-based therapies continues to accelerate, so too does competition to develop the next generation of medicines capable of challenging the established market leaders. California-based start-up, Structure Therapeutics, is among the many companiespursuing this opportunity, developing a pipeline of therapies targeting obesity, metabolic disorders, cardiovascular disease, and related conditions.
The company's share price rose sharply following the release of encouraging Phase II clinical data in late 2025 for its lead asset, aleniglipron, an oral, small-molecule GLP-1 receptor agonist. The results demonstrated competitive weight loss and a favourable tolerability profile, prompting considerable debate among investors as to whether aleniglipron could ultimately emerge as a best-in-class therapy, potentially surpassing Eli Lilly's Foundayo (orfoglipron). Investor enthusiasm propelled the company's valuation to approximately U.S.$5 billion.
However, sentiment reversed dramatically in 2026, with the share price declining approximately 70% from its January peak through 30 September 2026. In the absence of further compelling clinical catalysts, investors increasingly questioned the competitiveness of aleniglipron's clinical profile and the company's ability to execute its pivotal development programme. Meanwhile, intensifying competition across the obesity landscape, underwhelming additional pipeline data, and broader macroeconomic headwinds, including rising bond yields, further pressured the shares. Expectations of a potential acquisition also faded, partly reflecting management's publicly expressed reluctance to pursue a sale. We took advantage of intermittent share price strength in August to reduce our position, before ultimately exiting the investment shortly after the end of the half-year reporting period.
Stryker, a global leader in orthopaedics and surgicaltechnologies, experienced several company-specific disruptions in the first half of 2026, including a cybersecurity incident and supply-chain challenges in its vascular business. Share price weakness was the result, exacerbated by the challenging backdrop across all of Medical Technology, reflecting concerns about patient utilisation, the potential expiration of enhanced Affordable Care Act subsidies, and a more constrained hospital capital-spending environment. We exited our position as the second half outlook became less attractive. In our view, consensus assumptions for hip and knee replacement were increasingly difficult to achieve, whilst the previously signalled CEO transition added another element of uncertainty.
DERIVATIVE STRATEGY
The Company has the ability to utilise equity swaps and options as part of its financial strategy. Equity swaps are a financial tool (a derivative contract) that allow for synthetic exposure to a single stock (Single Stock Equity Swaps) or a group of stocks (Equity Basket Swaps).
Equity basket swaps are typically constructed within a well-defined theme; the basket format facilitates efficient management of the investment theme and easier tracking of performance. For example, maintaining 15 to 50+ additional positions at smaller weights (i.e. non-core) directly in the portfolio is often suboptimal. The equity basket swap contains multiple single stock long positions, with Goldman Sachs acting as the counterparty, ensuring confidence in forward trading and rebalancing strategies.
The Company strategically invested in one customised tactical basket swap targeting growth opportunities in undervalued small and mid-capitalisation Biotechnology, Pharmaceutical, and Medtech companies. This basket was constructed to capitalise on investment opportunities possessing considerable potential as attractive acquisition targets for larger corporations (M&A swap basket). During the period under review, the equity basket swap gained £11.0 million, accounting for 0.8% of the Company's total return for the half year. Single stock equity swaps, used to gain exposure to China, lost £2.7 million (detracting -0.3%) for the half-year period.
LEVERAGE STRATEGY
Historically, the typical leverage level employed by the Company has been in the low-double digits to mid-to-high teens range. Considering the market volatility since the COVID pandemic, we have, more recently, used leverage in a more tactical fashion.
In 2026, we have maintained a more bullish stance with end-of-month leverage ranging from 11% (our six-year average) to 19% (as performance inflected and our bullishness for a sustained move in Biotechnology and Pharmaceuticals increased).
The Company ended the period at 14.9%, underscoring our continued bullishness but with a nod to the possibility of further policy uncertainty, debate over another interest rate hike, and perhaps unforeseen geopolitical instability.
SECTOR DEVELOPMENTS
The six-month period witnessed several important developments across the global Healthcare industry, reinforcing our conviction that the sector is entering a new era of innovation, commercial opportunity and renewed investor interest. Perhaps most importantly, the regulatory environment for Pharmaceutical companies continued to stabilise, with the Trump administration expanding its landmark prescription drug pricing agreements to 26 manufacturers, representing approximately 90% of the U.S. branded drug market. This progress has helped reduce a longstanding source of investor uncertainty and allowed greater attention to return to the industry's underlying growth fundamentals.
Meanwhile, medical innovation continued at an impressive pace. The FDA approved 35 novel medicines during the calendar second and third quarters combined, including a particularly productive third quarter. Scientific advances across oncology, immunology, neurology and cardiometabolic disease continued to expand treatment possibilities and create new commercial opportunities.
The obesity treatment revolution also entered a new phase, highlighted by the approval and launch of Eli Lilly's oral GLP-1 therapy, expanding patient access including reimbursement for Medicare patients in the U.S., and exceptional commercial growth across the incretin category, particularly ex-U.S. At the same time, the increasing clinical adoption of molecular diagnostics and liquid biopsy technologies reinforced the emergence of precision medicine as an important new investment theme.
Biopharmaceutical M&A activity remained robust, supported by the strategic need for large Pharmaceutical companies to replenish their pipelines ahead of significant patent expirations. Conversely, Medical Technology and Managed Care experienced a more challenging environment, reflecting concerns surrounding procedure growth, reimbursement and earnings expectations.
The rapid adoption of AI across Healthcare presents another potentially transformative development. From accelerating drug discovery and clinical development to improving diagnostic accuracy and healthcare delivery, AI has the potential to amplify the industry's already impressive innovation cycle.
Collectively, we believe these developments reinforce the attractive long-term fundamentals of Healthcare investing, supported by accelerating innovation, expanding commercial markets and increasingly compelling valuations across selected areas of the sector.
OUTLOOK
Looking ahead, we intend to maintain our disciplined, bottom-up investment approach, focusing on companies with differentiated technologies, strong intellectual property, attractive growth prospects and management teams capable of converting scientific innovation into sustainable shareholder value.
Although the Trust's relative performance during the six-month period was modestly disappointing, the strong absolute return demonstrates the significant opportunities available across Healthcare. The exceptional contributions from Life Science Tools and Diagnostics, together with the continued success of several leading Pharmaceutical and Biotechnology investments, reinforce the potential of our differentiated approach.
Finally, the U.S. midterm elections were completed in November 2026. Whilst the outcome was perhaps of little doubt, the magnitude of the Democratic victory in both the U.S. Senate and U.S. House of Representatives was nothing short of extraordinary, representing a decisive repudiation of the Trump administration and a fundamental shift in the balance of political power in Washington. What is still up for debate, however, is what this means for healthcare going forward. Newly elected Representatives will take office in the New Year so what could be in store for 2027?
Of course, drug pricing is likely to be front and centre once again, or will it? The previous administration under Biden got their bill passed - with a reduction in Medicare drug pricing in the Inflation Reduction Act ("IRA"). The second Trump administration instituted Most Favoured Nation pricing across Medicaid and Medicare with landmark prescription drug pricing agreements with 26 manufacturers (representing approximately 90% of the U.S. branded drug market). It appears likely there may not be much left to do. That said, we expect the success of the Trump deals will give the Democrats both cause and motivation to heavily scrutinise these agreements and could create headline risk for the Bio-Pharma sector. Additionally, the Democrats may also look to expand the IRA, also leading to headline noise.
On the regulatory front, the departure of Robert F. Kennedy Jr. is being widely discussed. Whilst Kennedy's impact has lessened through his tenure, his departure from a policy seat would be welcomed by investors. However, the re-rise of Senator Bernie Sanders and his socialised medicine platform would not be taken well by the market.
Other issues we expect to be resolved in a positive manner. Public funding, such as through the National Institute of Healthcare, could be restored, and Trump's university funding could be reversed. Government funding cuts for federal health coverage such as the Affordable Care Act also could be reversed. Finally, there may be some debate around the potential for increased scrutiny over the recent surge in Biotechnology M&A, but we think small and mid-cap transactions will continue unabated.
Overall, we expect the rhetoric coming from Washington DC will surely increase as the political temperature and inflation rise in the U.S. That said, a Republican remains the President so despite the "blue wave" that swept Congress, we do expect only moderate changes going forward whilst more industry altering, calamitous legislation could still be dragged down in the quagmire of federal politics.
We remain convinced that the combination of accelerating medical innovation, favourable long-term demographic trends and attractive relative valuations creates a compelling backdrop for Healthcare investing.
Despite inevitable periods of volatility, we believe these structural drivers will continue to offer substantial opportunities to generate long-term shareholder returns.
Trevor M. Polischuk and Geoffrey C. Hsu
OrbiMed Capital LLC
Portfolio Manager
17 November 2026
Contribution by Investment
ABSOLUTE CONTRIBUTION BY INVESTMENT
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026
Principal contributors to and detractors from net asset value performance
|
|
|
| CONTRIBUTION |
|
|
| CONTRIBUTION | PER SHARE^ |
TOP FIVE CONTRIBUTORS | SECTOR | COUNTRY | £'000 | P |
Eli Lilly | Pharmaceuticals | North America | 40,777 | 11.3 |
Natera | Biotechnology | North America | 24,670 | 6.9 |
Guardant | Health Care Services | North America | 22,662 | 6.3 |
Caris Life Sciences | Life Sciences Tools | North America | 19,340 | 5.4 |
Humana* | Health Care Services | North America | 13,952 | 3.9 |
|
|
|
| CONTRIBUTION |
|
|
| CONTRIBUTION | PER SHARE |
TOP FIVE DETRACTORS | SECTOR | COUNTRY | £'000 | P |
Stryker | Health Care Equipment | North America | 6,456 | -1.8 |
Structure Therapeutics | Pharmaceuticals | North America | 6,556 | -1.8 |
Intuitive Surgical | Health Care Equipment | North America | 9,306 | -2.6 |
AstraZeneca | Pharmaceuticals | Europe | 15,394 | -4.3 |
Boston Scientific | Health Care Equipment | North America | 30,709 | -8.5 |
^ Calculation based on 359,597,924 shares being the weighted average number of shares in issue during the six months ended 30 September 2026.
* Not held at 30 September 2026.
Interim Management Report
PRINCIPAL RISKS AND UNCERTAINTIES
The Directors continue to review the Company's key risk register, which identifies the risks and uncertainties that the Company is exposed to, and the controls in place and the actions being taken to mitigate them.
A review of the half year and the outlook for the Company can be found in the Chair's Statement and the Portfolio Manager's Review.
The principal risks faced by the Company fall into the following broad categories: market risk; active management risk; portfolio performance; share price discount risk; unquoted investment risk; macro-economic, geopolitical and regulatory risks; counterparty and service provider risk; cyber risk; ESG related risk; and activism risk.
Further information on these risks is given in the Annual Report for the year ended 31 March 2026. The Company's principal risks and uncertainties have not changed materially since the date of that report and are not expected to change materially for the remaining six months of the Company's financial year.
RELATED PARTY TRANSACTIONS
During the first six months of the current financial year no material transactions with related parties have taken place which have affected the financial position or the performance of the Company.
GOING CONCERN
The Directors believe, having considered the Company's investment objectives, risk management policies, capital management policies and procedures, the nature of the portfolio and expenditure projections, that the Company has adequate resources, an appropriate financial structure and suitable management arrangements in place to continue in operational existence for the foreseeable future and, more specifically, that there are no material uncertainties relating to the Company that would prevent its ability to continue in such operational existence for at least 12 months from the date of the approval of this half yearly financial report. For these reasons, they consider there is reasonable evidence to continue to adopt the going concern basis in preparing the accounts.
DIRECTORS' RESPONSIBILITIES
The Board of Directors confirms that, to the best of its knowledge:
(i) the condensed set of financial statements contained within the Half Year Report have been prepared in accordance with Financial Reporting Standard 104 (Interim Financial Reporting); and
(ii) the interim management report includes a true and fair review of the information required by:
(a) DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
(b) DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.
The Half Year Report has not been reviewed or audited by the Company's auditors.
This Half Year Report contains certain forward-looking statements. These statements are made by the Directors in good faith based on the information available to them up to the date of this report and such statements should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying any such forward-looking information.
For and on behalf of the Board
William Hemmings
Chair
17 November 2026
Income Statement
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026
| (UNAUDITED) | (UNAUDITED) | ||||
| 30 SEPTEMBER 2026 | 30 SEPTEMBER 2025 | ||||
| REVENUE | CAPITAL |
| REVENUE | CAPITAL |
|
| RETURN | RETURN | TOTAL | RETURN | RETURN | TOTAL |
| £'000 | £'000 | £'000 | £'000 | £'000 | £'000 |
Gains on investments | - | 121,250 | 121,250 | - | 52,547 | 52,547 |
Exchange losses on currency balances | - | (2,151) | (2,151) | - | (2,844) | (2,844) |
Income from investments (note 2) | 6,525 | - | 6,525 | 5,438 | - | 5,438 |
AIFM, portfolio management, and performance fees (note 3) | (299) | (5,684) | (5,983) | (314) | (5,975) | (6,289) |
Other expenses | (561) | (63) | (624) | (665) | - | (665) |
Net return before finance charges and taxation | 5,665 | 113,352 | 119,017 | 4,459 | 43,728 | 48,187 |
Finance charges | (40) | (749) | (789) | (60) | (1,130) | (1,190) |
Net return before taxation | 5,625 | 112,603 | 118,228 | 4,399 | 42,598 | 46,997 |
Taxation | (860) | - | (860) | (63) | - | (63) |
Net return after taxation | 4,765 | 112,603 | 117,368 | 4,336 | 42,598 | 46,934 |
Return per share (note 4) | 1.3p | 31.3p | 32.6p | 0.9p | 9.3p | 10.2p |
The "Total" column of this statement is the Income Statement of the Company. The "Revenue" and "Capital" columns are supplementary to this and are prepared under guidance published by the Association of Investment Companies.
All revenue and capital items in the above statement derive from continuing operations.
The Company has no recognised gains and losses other than those shown above and therefore no separate Statement of Total Comprehensive Income has been presented.
The accompanying notes are an integral part of these statements.
Statement of Changes in Equity
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026
| (UNAUDITED) | (UNAUDITED) |
| 30 SEPTEMBER | 30 SEPTEMBER |
| 2026 | 2025 |
| £'000 | £'000 |
Opening shareholders' funds | 1,385,470 | 1,679,346 |
Shares purchased for treasury | (115,863) | (273,843) |
Return for the period | 117,368 | 46,934 |
Dividends paid - revenue | (6,161) | (8,174) |
Closing shareholders' funds | 1,380,814 | 1,444,263 |
Statement of Financial Position
AS AT 30 SEPTEMBER 2026
| (UNAUDITED) | (AUDITED) |
| 30 SEPTEMBER | 31 MARCH |
| 2026 | 2026 |
| £'000 | £'000 |
Fixed assets |
|
|
Investments | 1,421,436 | 1,304,264 |
Derivatives - OTC swaps | 467 | 6,511 |
| 1,421,903 | 1,310,775 |
Current assets |
|
|
Debtors | 10,699 | 49,459 |
Cash and cash equivalents | 54,645 | 70,821 |
| 65,344 | 120,280 |
Current liabilities |
|
|
Creditors: amounts falling due within one year | (94,580) | (42,864) |
Derivative - OTC Swaps | (11,853) | (2,721) |
| (106,433) | (45,585) |
Net current assets | (41,089) | 74,695 |
Total net assets | 1,380,814 | 1,385,470 |
Capital and reserves |
|
|
Ordinary share capital - (note 5) | 15,042 | 15,042 |
Capital redemption reserve | 9,564 | 9,564 |
Share premium account | 841,599 | 841,599 |
Capital reserve | 499,124 | 502,384 |
Revenue reserve | 15,485 | 16,881 |
Total shareholders' funds | 1,380,814 | 1,385,470 |
Net asset value per share - (note 6) | 403.6p | 371.1p |
Cash Flow Statement
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026
|
| (UNAUDITED) | (UNAUDITED) |
|
| SIX MONTHS ENDED | SIX MONTHS ENDED |
|
| 30 SEPTEMBER | 30 SEPTEMBER |
| NOTE | 2026 | 2025 |
| £'000 | £'000 | |
Net cash outflow from operating activities | 8 | (3,097) | (1,959) |
Purchases of investments and derivatives |
| (1,051,993) | (385,106) |
Sales of investments and derivatives |
| 1,090,886 | 609,006 |
Realised losses on foreign exchange |
| (2,131) | (2,690) |
Net cash inflow from investing activities |
| 36,762 | 221,210 |
Shares repurchased |
| (110,158) | (272,097) |
Equity dividends paid |
| (6,161) | (8,174) |
Interest paid |
| (789) | (1,190) |
Net cash outflow from financing activities |
| (117,108) | (281,461) |
Increase in net debt |
| (83,443) | (62,210) |
Cash flows from operating activities includes interest received of £1,067,000 (2025: £1,767,000) and dividends received of £5,556,000 (2025: £3,660,000).
RECONCILIATION OF NET CASH FLOW MOVEMENT TO MOVEMENT IN NET DEBT
| (UNAUDITED) | (UNAUDITED) |
| SIX MONTHS ENDED | SIX MONTHS ENDED |
| 30 SEPTEMBER | 30 SEPTEMBER |
| 2026 | 2025 |
| £'000 | £'000 |
Increase in net debt resulting from cash flows | (83,443) | (62,210) |
Losses on foreign currency cash and cash equivalents | (20) | (154) |
Movement in net debt in the period | (83,463) | (62,364) |
Net debt at 1 April | 51,944 | 25,511 |
Net debt at 30 September* | (31,519) | (36,853) |
* The net debt figure as at 30 September 2026 includes cash and cash equivalents less the overdraft drawn of £86,164,000 (30 September 2025: £68,120,000).
Notes to the Financial Statements
1. ACCOUNTING POLICIES
The condensed Financial Statements for the six months to 30 September 2026 comprise the statements set out on pages 25 to 31 of the Half-Year Report together with the related notes below. They have been prepared in accordance with FRS 104 'Interim Financial Reporting', the AIC's Statement of Recommended Practice published in July 2022 ('SORP') and using the same accounting policies as set out in the Company's Annual Report and Financial Statements at 31 March 2026.
Going concern
After making enquiries, and having reviewed the Investments, Statement of Financial Position and projected income and expenditure for the next 12 months, the Directors have a reasonable expectation that the Company has adequate resources to continue in operation for the foreseeable future. The Directors have therefore adopted the going concern basis in preparing these condensed financial statements.
Fair value
Under FRS 102 and FRS 104 investments have been classified using the following fair value hierarchy:
·Level 1 - Quoted market prices in active markets
·Level 2 - Prices of a recent transaction for identical instruments
·Level 3 - Valuation techniques that use:
(i) observable market data; or
(ii) non-observable data
| LEVEL 1 | LEVEL 2 | LEVEL 3 | TOTAL |
As at 30 September 2026 | £'000 | £'000 | £'000 | £'000 |
Investments held at fair value through profit or loss | 1,383,804 | - | 37,632 | 1,421,436 |
Derivatives: OTC swaps (assets) | - | 467 | - | 467 |
Derivatives: OTC swaps (liabilities) | - | (11,853) | - | (11,853) |
Financial instruments measured at fair value | 1,383,804 | (11,386) | 37,632 | 1,410,050 |
As at 31 March 2026 | LEVEL 1 | LEVEL 2 | LEVEL 3 | TOTAL |
£'000 | £'000 | £'000 | £'000 | |
Investments held at fair value through profit or loss | 1,267,795 | - | 36,469 | 1,304,264 |
Derivatives: OTC swaps (assets) | - | 6,511 | - | 6,511 |
Derivatives: OTC swaps (liabilities) | - | (2,721) | - | (2,721) |
Financial instruments measured at fair value | 1,267,795 | 3,790 | 36,469 | 1,308,054 |
2. INCOME
| (UNAUDITED) | (UNAUDITED) |
| SIX MONTHS ENDED | SIX MONTHS ENDED |
| 30 SEPTEMBER | 30 SEPTEMBER |
| 2026 | 2025 |
| £'000 | £'000 |
Investment income | 5,458 | 3,671 |
Interest income | 1,067 | 1,767 |
Total | 6,525 | 5,438 |
3. AIFM, PORTFOLIO MANAGEMENT AND PERFORMANCE FEES
| (UNAUDITED) | (UNAUDITED) | ||||
| SIX MONTHS ENDED | SIX MONTHS ENDED | ||||
| 30 SEPTEMBER 2026 | 30 SEPTEMBER 2025 | ||||
| REVENUE | CAPITAL | TOTAL | REVENUE | CAPITAL | TOTAL |
| £'000 | £'000 | £'000 | £'000 | £'000 | £'000 |
AIFM fee | 59 | 1,128 | 1,187 | 62 | 1,183 | 1,245 |
Portfolio management fee | 240 | 4,556 | 4,796 | 252 | 4,792 | 5,044 |
Performance fee charge for the period | - | - | - | - | - | - |
| 299 | 5,684 | 5,983 | 314 | 5,975 | 6,289 |
As at 30 September 2026 no performance fees were accrued or payable (31 March 2026: nil accrued).
No performance fee could become payable by 30 September 2027.
See Glossary for further information on the performance fee.
4. RETURN PER SHARE
| (UNAUDITED) | (UNAUDITED) |
| SIX MONTHS ENDED | SIX MONTHS ENDED |
| 30 SEPTEMBER | 30 SEPTEMBER |
| 2026 | 2025 |
| £'000 | £'000 |
The return per share is based on the following figures: |
|
|
Revenue return | 4,765 | 4,336 |
Capital return | 112,603 | 42,598 |
Total return | 117,368 | 46,934 |
Weighted average number of shares in issue for the period | 359,597,924 | 461,175,923 |
Revenue return per share | 1.3p | 0.9p |
Capital return per share | 31.3p | 9.3p |
Total return per share | 32.6p | 10.2p |
The calculation of the total, revenue and capital returns per ordinary share is carried out in accordance with IAS 33, "Earnings per Share (as adopted in the EU)".
5. SHARE CAPITAL
|
|
| TOTAL |
|
| TREASURY | SHARES |
| SHARES | SHARES | IN ISSUE |
| NUMBER | NUMBER | NUMBER |
As at 1 April 2026 | 373,412,417 | 228,252,783 | 601,665,200 |
Purchase of shares into treasury | (31,330,075) | 31,330,075 | - |
As at 30 September 2026 | 342,082,342 | 259,582,858 | 601,665,200 |
|
|
|
|
|
| (UNAUDITED) | (AUDITED) |
|
| 30 SEPTEMBER | 31 MARCH |
|
| 2026 | 2026 |
|
| £'000 | £'000 |
Issued and fully paid: |
|
|
|
Nominal value of ordinary shares of 2.5p ordinary shares (£000) |
| 15,042 | 15,042 |
During the period ended 30 September 2026 the Company bought back ordinary shares into treasury at a cost of £115.9m (Year ended 31 March 2026: £396.3m).
6. NET ASSET VALUE PER SHARE
The net asset value per share is based on the assets attributable to equity shareholders of £1,380,814,000 (31 March 2026: £1,385,470,000) and on the number of shares in issue at the period end of 342,082,342 (31 March 2026: 373,412,417).
7. TRANSACTION COSTS
Purchase transaction costs for the six months ended 30 September 2026 were £889,000 (six months ended 30 September 2025: £277,000). Sales transaction costs for the six months ended 30 September 2026 were £892,000 (six months ended 30 September 2025: £484,000).
These expenses are charged to the capital column of the Income Statement and included within Gains on investments.
8. RECONCILIATION OF OPERATING RETURN TO NET CASH OUTFLOW FROM OPERATING ACTIVITIES
| (UNAUDITED) | (UNAUDITED) |
| SIX MONTHS ENDED | SIX MONTHS ENDED |
| 30 SEPTEMBER | 30 SEPTEMBER |
| 2026 | 2025 |
| £'000 | £'000 |
Gains before finance costs and taxation | 119,017 | 48,187 |
Less: capital gains before finance charges and taxation | (113,590) | (43,728) |
Revenue return before finance charges and taxation | 5,427 | 4,459 |
Expenses charged to capital | (5,509) | (5,975) |
Decrease/(increase) in other debtors | 17 | (29) |
Decrease in other creditors and accruals | (2,638) | (97) |
Net taxation suffered on investment income | (394) | (317) |
Net cash outflow from operating activities | (3,097) | (1,959) |
9. PRINCIPAL RISKS AND UNCERTAINTIES
The principal risks facing the Company are listed in the Interim Management Report. An explanation of these risks and how they are managed is contained in the Strategic Report and note 16 of the Company's Annual Report & Accounts for the year ended 31 March 2026.
10. COMPARATIVE INFORMATION
The condensed financial statements contained in this half year report do not constitute statutory accounts as defined in section 434 of the Companies Act 2006. The financial information for the half years ended 30 September 2026 and 30 September 2025 has not been audited or reviewed by the Company's auditor.
The information for the year ended 31 March 2026 has been extracted from the latest published audited financial statements of the Company. Those financial statements have been filed with the Registrar of Companies. The report of the auditor on those financial statements was unqualified, did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying the report, and did not contain statements under either section 498 (2) or 498 (3) of the Companies Act 2006.
Earnings for the first six months should not be taken as a guide to the results for the full year.
Glossary of Terms and Alternative
Performance Measures ("APMs")
Alternative Investment Fund Managers Directive ("AIFMD")
Agreed by the European Parliament and the Council of the European Union and transposed into UK legislation, the AIFMD classifies certain investment vehicles, including investment companies, as Alternative Investment Funds ("AIFs") and requires them to appoint an Alternative Investment Fund Manager ("AIFM") and depositary to manage and oversee the operations of the investment vehicle. The Board of the Company retains responsibility for strategy, operations and compliance and the Directors retain a fiduciary duty to shareholders.
Benchmark
The performance of the Company is measured against the MSCI World Health Care Index on a net total return, sterling adjusted basis.
The net total return is calculated by reinvesting dividends after the deduction of withholding taxes.
Large Cap Biotech
Biotechnology company with fully integrated discovery, development and commercial capabilities and considered sustainably profitable.
Large Cap Pharma
Global, multinational pharmaceutical companies with fully integrated discovery, development and commercial capabilities.
Discount or premium
A description of the difference between the share price and the net asset value per share. The size of the discount or premium is calculated by subtracting the share price from the net asset value per share and then dividing by the net asset value per share. It is usually expressed as a percentage (%) of the net asset value per share. If the share price is higher than the net asset value per share the result is a premium. If the share price is lower than the net asset value per share, the shares are trading at a discount.
Emerging Biotech
Biotechnology company that does not fit the criteria of Large Cap Biotech, ranging from early-stage development to newly profitable.
Equity swaps
An equity swap is an agreement in which one party (counterparty) transfers the total return of an underlying equity position to the other party (swap holder) in exchange for a one-off payment at a set date. Total return includes dividend income and gains or losses from market movements. The exposure of the holder is the market value of the underlying equity position.
Your Company uses two types of equity swap:
· funded, where payment is made on acquisition. They are equivalent to holding the underlying equity position with the exception of additional counterparty risk and not possessing voting rights in the underlying; and,
· financed, where payment is made on maturity. As there is no initial outlay, financed swaps increase economic exposure by the value of the underlying equity position with no initial increase in the investments value - there is therefore embedded leverage within a financed swap due to the deferral of payment to maturity.
The Company employs swaps for two purposes:
· To gain access to individual stocks in the Indian, Chinese and other emerging markets, where the Company is not locally registered to trade or is able to gain in a more cost-efficient manner than holding the stocks directly; and,
· To gain exposure to thematic baskets of stocks (a Basket Swap). Basket Swaps are used to build exposure to themes, or ideas, that the Portfolio Manager believes the Company will benefit from and where holding a Basket Swap is more cost effective and operationally efficient than holding the underlying stocks or individual swaps.
Generics
Any therapeutics company, domestic or global, that focuses a majority of its efforts (not necessarily 100%) on developing and selling generic and/or biosimilar prescription and/or OTC products.
Leverage
Leverage is defined in the AIFMD as any method by which the AIFM increases the exposure of an AIF. In addition to the gearing limit the Company also has to comply with the AIFMD leverage requirements. For these purposes the Board has set a maximum leverage limit of 140% for both methods. This limit is expressed as a percentage with 100% representing no leverage or gearing in the Company. There are two methods of calculating leverage as follows:
The Gross Method is calculated as total exposure divided by Shareholders' Funds. Total exposure is calculated as net assets, less cash and cash equivalents, adding back cash borrowing plus derivatives converted into the equivalent position in their underlying assets.
The Commitment Method is calculated as total exposure divided by Shareholders' Funds. In this instance total exposure is calculated as net assets, less cash and cash equivalents, adding back cash borrowing plus derivatives converted into the equivalent position in their underlying assets, adjusted for netting and hedging arrangements.
| AS AT | AS AT | ||
| 30 SEPTEMBER 2026 | 31 MARCH 2026 | ||
| FAIR VALUE | EXPOSURE* | FAIR VALUE | EXPOSURE* |
| £'000 | £'000 | £'000 | £'000 |
Investments | 1,421,436 | 1,421,436 | 1,304,264 | 1,304,264 |
OTC equity swaps | (11,386) | 165,350 | 3,790 | 254,852 |
| 1,410,050 | 1,586,786 | 1,310,775 | 1,559,116 |
Shareholders' funds |
| 1,380,814 |
| 1,385,470 |
Leverage % |
| 14.9% |
| 12.5% |
* Calculated in accordance with AIFMD requirements using the Commitment Method
MSCI World Health Care Index (the Company's Benchmark)
The MSCI information (relating to the Benchmark) may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation lost profits) or any other damages. (www.msci.com)
Net asset value (NAV) Total return ("APM")
The theoretical total return on shareholders' funds per share, reflecting the change in NAV assuming that dividends paid to shareholders were reinvested at NAV at the time the shares were quoted ex-dividend. A way of measuring investment management performance of investment trusts which is not affected by movements in discounts/premiums.
| SIX MONTHS TO | YEAR TO |
| 30 SEPTEMBER | 31 MARCH |
| 2026 | 2026 |
| (p) | (p) |
Opening NAV per share | 371.0 | 339.5 |
Increase in NAV per share | 32.6 | 31.5 |
Closing NAV per share | 403.6 | 371.0 |
% increase in NAV | 8.8% | 9.3% |
Impact of reinvested dividends | 0.5% | 0.7% |
NAV per share Total Return | 9.3% | 10.0% |
Ongoing charges ("APM")
Ongoing charges are calculated by taking the Company's annualised ongoing charges, excluding finance costs, taxation, performance fees and exceptional items, and expressing them as a percentage of the average daily net asset value of the Company over the year.
| SIX MONTHS TO | ONE YEAR TO |
| 30 SEPTEMBER | 31 MARCH |
| 2026 | 2026 |
| £'000 | £'000 |
AIFM & Portfolio Management fees | 5,983 | 12,389 |
Other Expenses | 561 | 1,394 |
Total Ongoing Charges | 6,544 | 13,783 |
Performance fees paid/crystallised | - | - |
Total | 6,544 | 13,783 |
Average net assets | 1,417,799 | 1,517,239 |
Ongoing Charges (annualised) | 0.9% | 0.9% |
Ongoing Charges (annualised, including performance fees paid or crystallised during the period) | 0.9% | 0.9% |
Performance Fee
Dependent on the level of long-term outperformance of the Company, a performance fee can become payable. The performance fee is calculated by reference to the amount by which the Company's NAV performance has outperformed the Benchmark.
The fee is calculated quarterly by comparing the cumulative performance of the Company's NAV with the cumulative performance of the Benchmark since the launch of the Company in 1995. Provision is also made within the daily NAV per share calculation as required and in accordance with generally accepted accounting standards. The performance fee amounts to 15.0% of any outperformance over the Benchmark (see Company's Annual Report & Accounts for the year ended 31 March 2024 for further information).
In order to ensure that only sustained outperformance is rewarded, at each quarterly calculation date any performance fee payable is based on the lower of:
i) The cumulative outperformance of the investment portfolio over the Benchmark as at the quarter end date; and
ii) The cumulative outperformance of the investment portfolio over the Benchmark as at the corresponding quarter end date in the previous year.
The effect of this is that outperformance has to be maintained for a 12-month period before the related fee is paid.
In addition, a performance fee only becomes payable to the extent that the cumulative outperformance gives rise to a total fee greater than the total of all performance fees paid to date.
Share Price Total Return ("APM")
Return to the investor on mid-market prices assuming that all dividends paid were reinvested.
| SIX MONTHS TO | ONE YEAR TO |
| 30 SEPTEMBER | 31 MARCH |
| 2026 | 2026 |
| (p) | (p) |
Opening share price | 334.0 | 297.5 |
Increase in share price | 47.5 | 36.5 |
Closing share price | 381.5 | 334.0 |
% increase in share price | 14.2% | 12.3% |
Impact of reinvested dividends | 0.6% | 0.8% |
Share price Total Return | 14.8% | 13.1% |
Spec Pharma
Any other therapeutics company that does not fit the criteria of Large Cap Pharma that develops and sell pharmaceutical products, often focused on a limited number of therapeutic areas (or technologies), with a domestic and sometimes global footprint.
Frostrow Capital LLP
Company Secretary
17 November 2026
- ENDS -


